Abbott Laboratories $ABT Position Boosted by Meeder Advisory Services Inc.

Meeder Advisory Services Inc. raised its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 18.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 42,118 shares of the healthcare product maker’s stock after purchasing an additional 6,608 shares during the period. Meeder Advisory Services Inc.’s holdings in Abbott Laboratories were worth $4,162,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ABT. BlackRock Inc. raised its position in shares of Abbott Laboratories by 4.6% during the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after purchasing an additional 6,769,518 shares during the last quarter. State Street Corp grew its holdings in Abbott Laboratories by 0.6% during the 3rd quarter. State Street Corp now owns 81,431,110 shares of the healthcare product maker’s stock valued at $8,047,837,000 after buying an additional 504,876 shares during the last quarter. Bank of America Corp DE acquired a new stake in Abbott Laboratories during the 2nd quarter valued at $1,603,607,000. Deutsche Bank AG increased its position in Abbott Laboratories by 18.6% during the second quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker’s stock worth $1,515,963,000 after buying an additional 2,614,965 shares in the last quarter. Finally, Legal & General Group Plc purchased a new position in Abbott Laboratories during the second quarter worth $1,082,524,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories News Summary

Investors following ABT have been watching these news items:

  • Positive Sentiment: Leerink Partners upgraded Abbott from “market perform” to “outperform” and set a $124 price target, citing a more favorable outlook for the company. The higher rating is a potential bullish catalyst. Article
  • Positive Sentiment: Abbott initiated the VOYAGER CE trial of its investigational Encantor software-guided TAVI system for severe aortic stenosis. The technology is designed to improve valve deployment; successful development could strengthen Abbott’s cardiovascular device pipeline, though clinical and regulatory outcomes remain uncertain. Article
  • Neutral Sentiment: Articles noting that ABT is up 1.3% since its last earnings report revisit the results and look to earnings estimates for clues, but provide no specific new estimate revisions or fresh financial results. Article

Insider Activity

In other news, EVP Mary Moreland sold 3,500 shares of the business’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $116.00, for a total transaction of $406,000.00. Following the completion of the sale, the executive vice president directly owned 100,791 shares of the company’s stock, valued at $11,691,756. The trade was a 3.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Trading Down 0.9%

Shares of Abbott Laboratories stock opened at $102.96 on Friday. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $129.85. The business’s fifty day moving average is $103.91 and its two-hundred day moving average is $101.66. The company has a quick ratio of 1.00, a current ratio of 1.45 and a debt-to-equity ratio of 0.57. The firm has a market cap of $178.32 billion, a PE ratio of 38.42, a P/E/G ratio of 1.81 and a beta of 0.54.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, meeting analysts’ consensus estimates of $1.42. Abbott Laboratories had a net margin of 9.75% and a return on equity of 18.04%. The company had revenue of $13.01 billion during the quarter, compared to the consensus estimate of $12.99 billion. During the same quarter in the prior year, the company posted $1.30 EPS. The company’s quarterly revenue was up 14.5% compared to the same quarter last year. Analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, November 16th. Shareholders of record on Thursday, October 15th were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date was Thursday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 94.03%.

Wall Street Analysts Forecast Growth

ABT has been the topic of several recent research reports. Citigroup reduced their price objective on Abbott Laboratories from $125.00 to $122.00 and set a “buy” rating on the stock in a research report on Thursday, October 22nd. Royal Bank Of Canada cut their target price on shares of Abbott Laboratories from $130.00 to $125.00 and set an “outperform” rating for the company in a research note on Thursday, October 22nd. TD Cowen cut their target price on shares of Abbott Laboratories from $135.00 to $118.00 and set a “buy” rating for the company in a research note on Thursday, October 22nd. Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 target price on the stock in a report on Thursday, August 13th. Finally, UBS Group decreased their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $119.04.

Get Our Latest Analysis on ABT

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

Recommended Stories

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.